Agonist
Novo Nordisk Reports Significant Weight Loss with New Dual-Acting Oral Drug in Early Clinical Trial
Novo Nordisk, weight loss, dual-acting oral drug, early clinical trial, obesity treatment, GLP-1 receptor agonist
Centessa’s ORX750 Demonstrates Promising ‘Best-in-Class’ Profile in Early Narcolepsy Trial
Centessa Pharmaceuticals, ORX750, narcolepsy, orexin receptor 2 agonist, sleep-wake disorders, clinical trial, Phase 1 data
Terns Pharmaceuticals’ Oral GLP-1R Agonist TERN-601 Shows Promising Weight Loss in Phase 1 Trial
Terns Pharmaceuticals, TERN-601, Oral GLP-1R Agonist, Phase 1 Trial, Weight Loss, Obesity Treatment
ImmunityBio Secures FDA Approval for ANKTIVA but Faces Financial Challenges
ImmunityBio, FDA approval, ANKTIVA, financial troubles, cancer treatment, IL-15 agonist immunotherapy
Syros Discontinues Mid-Stage Tamibarotene Program in Frontline Acute Myeloid Leukemia (AML)
Syros Pharmaceuticals, Tamibarotene, Acute Myeloid Leukemia (AML), Clinical Trial, SELECT-AML-1, Venetoclax, Azacitidine, RARα Agonist, Futility Analysis
RAPT Therapeutics Announces Significant Workforce Reduction Following Clinical Hold on Zelnecirnon Trials
RAPT Therapeutics, zelnecirnon, clinical hold, workforce reduction, FDA, clinical trials, atopic dermatitis, asthma, oncology, CCR4 agonist
Lilly’s Tirzepatide Wins NICE Endorsement for Obesity Treatment with BMI and Weight Loss Conditions
Lilly, tirzepatide, NICE endorsement, obesity treatment, BMI, weight loss, Zepbound, Mounjaro, GLP-1 receptor agonist
Takeda’s Orexin Narcolepsy Drug TAK-861 Poised for Phase III Trials After Promising Results
Takeda, TAK-861, narcolepsy, orexin receptor 2 agonist, Phase III trials, narcolepsy type 1, sleep disorders
Minimal Weight Reduction Observed with Low Doses of New Zealand’s GLP-1/GLP-2 Agonist
New Zealand, GLP-1/GLP-2 agonist, weight reduction, lowest doses, minimal effect.